Sagent Pharmaceuticals Given Hold Rating at JPMorgan Chase & Co. (SGNT)
Sagent Pharmaceuticals (NASDAQ:SGNT)‘s stock had its “hold” rating reiterated by JPMorgan Chase & Co. in a research note issued on Wednesday, AR Network reports. They currently have a $24.00 price target on the stock, up from their previous price target of $22.00. JPMorgan Chase & Co.’s target price would suggest a potential upside of 13.05% from the stock’s previous close.
Shares of Sagent Pharmaceuticals (NASDAQ:SGNT) opened at 21.24 on Wednesday. Sagent Pharmaceuticals has a 52-week low of $15.71 and a 52-week high of $26.08. The stock has a 50-day moving average of $21.63 and a 200-day moving average of $22.20. The company has a market cap of $676.8 million and a price-to-earnings ratio of 26.15.
Sagent Pharmaceuticals (NASDAQ:SGNT) last announced its earnings results on Tuesday, May 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.18. The company had revenue of $70.90 million for the quarter, compared to the consensus estimate of $65.66 million. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. On average, analysts predict that Sagent Pharmaceuticals will post $0.15 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on SGNT. Analysts at Jefferies Group reiterated a “hold” rating on shares of Sagent Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Sagent Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $23.62.
Sagent Pharmaceuticals, Inc (NASDAQ:SGNT) is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.